Oncocyte’s Proprietary Assay Demonstrates Long-Term Clinical Validity

Study Findings: Oncocyte Corp. published positive data from a study involving 131 patients that supports the use of their blood-based transplant rejection assay, revealing significant correlations between elevated dd-cfDNA levels and organ rejection, which enhances understanding of transplant biology.

Market Expansion Potential: The findings indicate opportunities for Oncocyte to expand its market by monitoring high-risk kidney transplant patients long-term, as the assay remains clinically valid even years post-transplant, with implications for routine screening in managing transplant rejections.